8-K: Baxter International Appoints Andrew Hider as New CEO, Brent Shafer Transitions to Non-Executive Chair

Baxter International Inc. announced the appointment of Andrew Hider as its new President and Chief Executive Officer, effective no later than September 3, 2025, with interim CEO Brent Shafer transitioning to non-executive Chair of the Board.

Summary

• Baxter International Inc. has appointed Andrew Hider as its new President and Chief Executive Officer, effective on the earlier of September 3, 2025, or an agreed-upon date, subject to his current contractual obligations.
• Mr. Hider will also join the Board of Directors, increasing the board's authorized number of directors to eleven.
• Brent Shafer, who served as interim CEO since February 2025, will transition to the non-executive Chair of the Board and rejoin the Audit Committee and the Nominating, Corporate Governance and Public Policy Committee as an independent director, effective upon Mr. Hider's start date.
• Mr. Hider's compensation package includes an annual base salary of $1,350,000, a target annual bonus opportunity of 150% of his base salary (prorated for 2025), and eligibility for an initial target annual equity grant value of $14,000,000 (prorated for 2025).
• He will also receive a one-time supplemental cash payment of $1,000,000 (minus applicable taxes) and a one-time supplemental equity award with a target grant value of $4,000,000 in Performance Share Units (PSUs).
• Additionally, Mr. Hider will receive a 'Make Whole Award' totaling $8,500,000 ($5,750,000 in Restricted Stock Units (RSUs) and $2,750,000 in PSUs) to compensate for unvested equity from his prior employer.
• Mr. Hider's prior experience includes serving as CEO of ATS Corporation since 2017, where he significantly grew adjusted revenues and EBITDA, and ATS's stock price more than tripled on the TSX since his appointment.

Sentiment

Score: 8

Explanation: The announcement of a new CEO with a proven track record of driving growth and shareholder value at a comparable global company, coupled with a clear transition plan for the interim CEO, is a strong positive signal for the company's future strategic direction and operational performance.

Positives

• Appointment of Andrew Hider, an experienced leader with a strong track record of operational excellence, disciplined execution, and innovation.
• Under Mr. Hider's leadership at ATS Corporation, adjusted revenues nearly doubled over a five-year period, representing a low-to-mid teens compound annual growth rate (CAGR), with similar adjusted EBITDA CAGR.
• ATS's stock price more than tripled on the TSX since Mr. Hider's appointment in 2017, significantly outperforming major indices over the same period.
• Mr. Hider's experience at ATS, a global, diversified, customer-centric company with a significant life sciences segment, aligns well with Baxter's operations and strategic direction.
• Brent Shafer's transition to non-executive Chair provides continuity in board leadership and leverages his experience while allowing for new executive leadership.
• The comprehensive compensation package is designed to attract and retain top-tier executive talent, including significant equity incentives and a 'Make Whole Award' for prior unvested equity.

Risks

• The effective date of Andrew Hider's appointment is subject to his compliance with existing contractual obligations to his current employer, which could potentially delay his start beyond September 3, 2025.
• The one-time supplemental cash payment of $1,000,000 is subject to a clawback provision: 100% repayment if Mr. Hider resigns (other than for Good Reason) within 12 months of the Effective Date, and 50% repayment if he resigns between 12 and 24 months following the Effective Date.

Future Outlook

Management anticipates that the new leadership will accelerate innovation, further enhance performance, redefine healthcare delivery, and drive sustainable, long-term growth for Baxter International Inc.

Management Comments

• "Andrew is an exceptional leader with a strong track record of operational excellence, disciplined execution and innovation. We are excited that he will be Baxters next CEO." Brent Shafer
• "Andrews leadership at global, diversified companies underscores his ability to manage complex operations and generate value for shareholders while maintaining a focus on quality and important customer-centric missions. We are confident he is the right executive to lead Baxter into its next chapter." Brent Shafer
• "I am energized by Baxters mission-driven culture and strong legacy of creating medically essential products that help address patients and customers most pressing needs." Andrew Hider
• "Baxter has undergone a significant transformation over the last few years, refocusing the company and better positioning it for the future. I look forward to partnering with the Board and working alongside my talented future colleagues to accelerate innovation, further enhance our performance and redefine healthcare delivery while driving sustainable, long-term growth." Andrew Hider

Industry Context

The appointment of a new CEO with a strong background in advanced automation solutions and life sciences, particularly from a company like ATS Corporation, suggests Baxter's strategic focus on leveraging technology and operational efficiency within the evolving medtech and healthcare delivery landscape. This move aligns with broader industry trends emphasizing innovation, digital transformation, and optimized supply chains to meet patient and customer needs more effectively.

Comparison to Industry Standards

• Andrew Hider's leadership at ATS Corporation resulted in adjusted revenues nearly doubling over a five-year period, representing a low-to-mid teens compound annual growth rate (CAGR), and similar adjusted EBITDA CAGR over the same period. This demonstrates strong growth performance that would be considered favorable against industry peers.
• Since Mr. Hider's appointment in 2017, ATS's stock price more than tripled on the TSX, significantly outperforming major indices over the same period, indicating superior shareholder value creation compared to broader market benchmarks.
• ATS Corporation, under Mr. Hider, optimized its portfolio by strategically shifting investments towards higher-growth end markets, a common strategy among leading companies in the life sciences and technology sectors to enhance competitiveness and market position.
• ATS's largest end-market becoming its life sciences segment, where it enables automation solutions for medical devices, diagnostics, pharmaceutical, and laboratory operations, positions Mr. Hider with highly relevant experience for Baxter's core business as a global medtech leader, suggesting a strategic alignment with industry demands for advanced healthcare solutions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Expected positive impact due to the appointment of a new CEO with a strong track record of driving growth and shareholder value, potentially leading to increased share price and long-term value creation.
• Employees: New leadership may bring strategic shifts and operational changes, potentially impacting roles and organizational structure, but also offering new opportunities under a growth-oriented leader.
• Customers: The new CEO's focus on accelerating innovation and redefining healthcare delivery could lead to enhanced products, solutions, and customer service.
• Suppliers: Potential for changes in supply chain strategies or partnerships as the new leadership implements its vision for operational excellence.
• Creditors: Stable leadership and a focus on sustainable growth could reinforce financial health, positively impacting creditworthiness.

Next Steps

• Andrew Hider's official start as President and CEO, and Director, on the Effective Date (earlier of September 3, 2025, or an agreed-upon date).
• Brent Shafer's transition to non-executive Chair of the Board and rejoining the Audit Committee and Nominating, Corporate Governance and Public Policy Committee, effective on Mr. Hider's start date.
• Filing of the Shafer Amendment with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
• Mr. Hider's proposed Board appointment is subject to re-election by Baxter stockholders at the 2026 Annual Meeting of the Company in May 2026.
• Mr. Hider's next annual equity grant is scheduled for March 2026.

Key Dates

Recommendation

Keywords

CEO appointment, Executive change, Corporate governance, Leadership transition, Medical technology, Healthcare, SEC filing, Baxter International, Andrew Hider, Brent Shafer